LivaNova (NASDAQ:LIVN) Announces Earnings Results

LivaNova (NASDAQ:LIVN) released its quarterly earnings results on Wednesday. The company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.80 by $0.06, FiscalAI reports. LivaNova had a negative net margin of 16.12% and a positive return on equity of 15.98%. The company had revenue of $360.90 million during the quarter, compared to analysts’ expectations of $354.31 million. During the same quarter in the prior year, the company earned $0.81 earnings per share. The business’s quarterly revenue was up 12.2% compared to the same quarter last year. LivaNova updated its FY 2026 guidance to 4.150-4.250 EPS.

Here are the key takeaways from LivaNova’s conference call:

• The company reported double-digit organic revenue growth and 150 basis points of adjusted operating margin expansion in 2025, with strong cash generation and a 2026 revenue guide of +6% to +7% consistent with its Investor Day framework.
• LivaNova advanced its obstructive sleep apnea (OSA) program with a planned PMA approval for the clinical device in H1 2026, a follow-on MRI-compatible supplement and a commercial rollout targeting 2027, while highlighting the OSPREY RCT and the PolySync algorithm that management says can convert many non-responders.
• Epilepsy benefits from two near-term tailwinds: the CORE‑VNS clinical data
• Near‑term risks include third‑party component constraints for oxygenators, higher capital and R&D spend (2026 capex guidance ~$120M) to scale manufacturing and advance OSA, modest tariff exposure, and a reserved SNIA-related cash obligation (~$400M potential Q3 payment) that management says remains the company’s best estimate of the liability.

LivaNova Stock Up 1.4%

Shares of NASDAQ:LIVN traded up $0.94 during midday trading on Wednesday, hitting $69.99. The stock had a trading volume of 794,831 shares, compared to its average volume of 694,501. The company has a market cap of $3.82 billion, a P/E ratio of -17.49 and a beta of 0.97. LivaNova has a 12 month low of $32.48 and a 12 month high of $70.32. The business’s 50-day simple moving average is $64.26 and its 200-day simple moving average is $58.73. The company has a quick ratio of 1.12, a current ratio of 1.33 and a debt-to-equity ratio of 0.30.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Pacer Advisors Inc. increased its stake in shares of LivaNova by 131.7% during the 4th quarter. Pacer Advisors Inc. now owns 16,661 shares of the company’s stock worth $1,025,000 after purchasing an additional 9,471 shares during the last quarter. Invesco Ltd. increased its position in LivaNova by 4.5% during the fourth quarter. Invesco Ltd. now owns 1,091,086 shares of the company’s stock worth $67,135,000 after buying an additional 47,323 shares during the last quarter. Corient Private Wealth LLC bought a new stake in LivaNova in the fourth quarter valued at approximately $604,000. Mercer Global Advisors Inc. ADV bought a new stake in LivaNova in the fourth quarter valued at approximately $306,000. Finally, State of Tennessee Department of Treasury lifted its position in shares of LivaNova by 44.9% in the fourth quarter. State of Tennessee Department of Treasury now owns 30,304 shares of the company’s stock valued at $1,991,000 after buying an additional 9,396 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on LIVN. Piper Sandler reiterated an “overweight” rating and set a $85.00 target price on shares of LivaNova in a report on Thursday, February 19th. Needham & Company LLC increased their price objective on LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Barclays raised their price target on shares of LivaNova from $58.00 to $67.00 and gave the stock an “equal weight” rating in a research note on Friday, January 9th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of LivaNova in a research report on Monday, December 29th. Seven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $73.00.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.

Read More

• Five stocks we like better than LivaNova
• The gold chart Wall Street is terrified of…
• America’s 1776 happening again
• Buy this Gold Stock Before May 2026
• This makes me furious
• What a Former CIA Agent Knows About the Coming Collapse